Catalyst Other Current Liab vs Short Term Investments Analysis

CPRX Stock

USD 14.89 0.21 1.43%

Catalyst Pharmaceuticals financial indicator trend analysis is way more than just evaluating Catalyst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Catalyst Pharmaceuticals is a good investment. Please check the relationship between Catalyst Pharmaceuticals Other Current Liab and its Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Other Current Liab vs Short Term Investments

Other Current Liab vs Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Catalyst Pharmaceuticals Other Current Liab account and Short Term Investments. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Catalyst Pharmaceuticals' Other Current Liab and Short Term Investments is -0.52. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of Catalyst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Catalyst Pharmaceuticals' Other Current Liab and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Catalyst Pharmaceuticals are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Other Current Liab i.e., Catalyst Pharmaceuticals' Other Current Liab and Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.52

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Other Current Liab

Short Term Investments

Short Term Investments is an item under the current assets section of Catalyst Pharmaceuticals balance sheet. It contains any investments Catalyst Pharmaceuticals undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Catalyst Pharmaceuticals can easily liquidate in the marketplace.

Most indicators from Catalyst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Catalyst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.At this time, Catalyst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 19.7 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.11 in 2024.

	2023	2024 (projected)
Reconciled Depreciation	24.4M	25.6M
Net Interest Income	1.8M	1.0M

Reconciled Depreciation Net Interest Income

Catalyst Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Common Stock Total Equity	Property Plant And Equipment Gross	Common Stock	Property Plant Equipment	Non Currrent Assets Other	Other Current Assets	Net Receivables	Other Liab	Non Current Liabilities Total	Net Tangible Assets
Total Assets		1.0	-0.79	0.82	0.3	0.78	0.49	0.8	0.98	0.91	0.91	0.99	0.91	0.79	0.9	0.89	0.51	0.93	0.48	0.47	-0.8	0.93	0.84	0.86	0.8	0.99
Total Stockholder Equity	1.0		-0.79	0.81	0.32	0.79	0.5	0.81	0.98	0.91	0.9	0.98	0.91	0.79	0.9	0.89	0.53	0.93	0.5	0.48	-0.8	0.93	0.83	0.86	0.78	0.99
Net Debt	-0.79	-0.79		-1.0	-0.65	-0.99	-0.63	-0.74	-0.78	-0.97	-0.64	-0.75	-0.81	-0.52	-0.47	-0.44	-0.6	-0.77	-0.61	-0.54	0.33	-0.63	-0.35	-0.82	-0.88	-0.84
Cash	0.82	0.81	-1.0		0.64	0.99	0.62	0.75	0.81	0.97	0.66	0.77	0.83	0.54	0.5	0.47	0.59	0.79	0.6	0.54	-0.36	0.65	0.38	0.83	0.89	0.86
Other Assets	0.3	0.32	-0.65	0.64		0.65	0.46	0.39	0.22	0.55	0.01	0.21	0.31	0.12	-0.01	-0.03	0.4	0.26	0.43	0.48	0.13	0.3	-0.18	0.53	0.43	0.42
Cash And Short Term Investments	0.78	0.79	-0.99	0.99	0.65		0.69	0.79	0.76	0.97	0.62	0.73	0.81	0.46	0.45	0.42	0.66	0.77	0.67	0.57	-0.33	0.61	0.35	0.79	0.86	0.84
Common Stock Shares Outstanding	0.49	0.5	-0.63	0.62	0.46	0.69		0.86	0.44	0.66	0.28	0.44	0.46	-0.08	0.33	0.21	0.98	0.43	0.98	0.39	-0.31	0.45	0.27	0.56	0.38	0.56
Other Stockholder Equity	0.8	0.81	-0.74	0.75	0.39	0.79	0.86		0.74	0.84	0.6	0.76	0.71	0.27	0.68	0.59	0.87	0.71	0.87	0.46	-0.62	0.76	0.63	0.76	0.55	0.84
Total Liab	0.98	0.98	-0.78	0.81	0.22	0.76	0.44	0.74		0.89	0.95	1.0	0.9	0.81	0.89	0.88	0.45	0.92	0.42	0.39	-0.78	0.89	0.82	0.85	0.84	0.96
Total Current Assets	0.91	0.91	-0.97	0.97	0.55	0.97	0.66	0.84	0.89		0.76	0.87	0.89	0.61	0.66	0.63	0.64	0.87	0.64	0.56	-0.54	0.77	0.56	0.87	0.87	0.95
Other Current Liab	0.91	0.9	-0.64	0.66	0.01	0.62	0.28	0.6	0.95	0.76		0.94	0.79	0.83	0.86	0.89	0.31	0.83	0.27	0.19	-0.79	0.79	0.85	0.65	0.81	0.85
Total Current Liabilities	0.99	0.98	-0.75	0.77	0.21	0.73	0.44	0.76	1.0	0.87	0.94		0.89	0.81	0.92	0.91	0.46	0.92	0.43	0.39	-0.82	0.92	0.86	0.86	0.78	0.96
Property Plant And Equipment Net	0.91	0.91	-0.81	0.83	0.31	0.81	0.46	0.71	0.9	0.89	0.79	0.89		0.73	0.73	0.74	0.45	0.99	0.43	0.74	-0.64	0.75	0.67	0.81	0.75	0.91
Retained Earnings	0.79	0.79	-0.52	0.54	0.12	0.46	-0.08	0.27	0.81	0.61	0.83	0.81	0.73		0.75	0.84	-0.05	0.77	-0.1	0.3	-0.65	0.72	0.7	0.61	0.7	0.74
Accounts Payable	0.9	0.9	-0.47	0.5	-0.01	0.45	0.33	0.68	0.89	0.66	0.86	0.92	0.73	0.75		0.98	0.38	0.79	0.33	0.25	-0.94	0.94	0.97	0.74	0.52	0.85
Non Current Assets Total	0.89	0.89	-0.44	0.47	-0.03	0.42	0.21	0.59	0.88	0.63	0.89	0.91	0.74	0.84	0.98		0.26	0.81	0.21	0.26	-0.93	0.91	0.97	0.68	0.55	0.84
Common Stock Total Equity	0.51	0.53	-0.6	0.59	0.4	0.66	0.98	0.87	0.45	0.64	0.31	0.46	0.45	-0.05	0.38	0.26		0.43	0.99	0.36	-0.33	0.48	0.33	0.54	0.35	0.58
Property Plant And Equipment Gross	0.93	0.93	-0.77	0.79	0.26	0.77	0.43	0.71	0.92	0.87	0.83	0.92	0.99	0.77	0.79	0.81	0.43		0.41	0.69	-0.71	0.79	0.75	0.82	0.74	0.93
Common Stock	0.48	0.5	-0.61	0.6	0.43	0.67	0.98	0.87	0.42	0.64	0.27	0.43	0.43	-0.1	0.33	0.21	0.99	0.41		0.37	-0.28	0.44	0.28	0.52	0.34	0.55
Property Plant Equipment	0.47	0.48	-0.54	0.54	0.48	0.57	0.39	0.46	0.39	0.56	0.19	0.39	0.74	0.3	0.25	0.26	0.36	0.69	0.37		-0.21	0.33	0.2	0.52	0.3	0.53
Non Currrent Assets Other	-0.8	-0.8	0.33	-0.36	0.13	-0.33	-0.31	-0.62	-0.78	-0.54	-0.79	-0.82	-0.64	-0.65	-0.94	-0.93	-0.33	-0.71	-0.28	-0.21		-0.84	-0.95	-0.6	-0.42	-0.74
Other Current Assets	0.93	0.93	-0.63	0.65	0.3	0.61	0.45	0.76	0.89	0.77	0.79	0.92	0.75	0.72	0.94	0.91	0.48	0.79	0.44	0.33	-0.84		0.86	0.87	0.58	0.91
Net Receivables	0.84	0.83	-0.35	0.38	-0.18	0.35	0.27	0.63	0.82	0.56	0.85	0.86	0.67	0.7	0.97	0.97	0.33	0.75	0.28	0.2	-0.95	0.86		0.6	0.43	0.77
Other Liab	0.86	0.86	-0.82	0.83	0.53	0.79	0.56	0.76	0.85	0.87	0.65	0.86	0.81	0.61	0.74	0.68	0.54	0.82	0.52	0.52	-0.6	0.87	0.6		0.68	0.89
Non Current Liabilities Total	0.8	0.78	-0.88	0.89	0.43	0.86	0.38	0.55	0.84	0.87	0.81	0.78	0.75	0.7	0.52	0.55	0.35	0.74	0.34	0.3	-0.42	0.58	0.43	0.68		0.79
Net Tangible Assets	0.99	0.99	-0.84	0.86	0.42	0.84	0.56	0.84	0.96	0.95	0.85	0.96	0.91	0.74	0.85	0.84	0.58	0.93	0.55	0.53	-0.74	0.91	0.77	0.89	0.79

Click cells to compare fundamentals

Catalyst Pharmaceuticals Account Relationship Matchups

Catalyst Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	112.4M	192.4M	237.8M	375.6M	471.9M	495.5M
Total Stockholder Equity	87.6M	169.6M	206.8M	300.4M	387.9M	407.3M
Net Debt	(88.9M)	(130.2M)	(167.6M)	(294.5M)	(134.1M)	(127.4M)
Cash	89.5M	130.2M	171.4M	298.4M	137.6M	144.5M
Cash And Short Term Investments	94.5M	140.3M	191.3M	298.4M	137.6M	144.5M
Common Stock Shares Outstanding	106.0M	106.2M	107.8M	111.4M	113.8M	57.0M
Liabilities And Stockholders Equity	112.4M	192.4M	237.8M	375.6M	471.9M	495.5M
Other Stockholder Equity	216.2M	223.2M	233.2M	250.4M	266.5M	279.8M
Total Liab	24.7M	22.8M	31.0M	75.2M	84.0M	88.2M
Total Current Assets	111.4M	159.2M	210.1M	320.8M	219.3M	230.3M
Other Current Liab	172.3K	107.0K	243K	53.3M	60.2M	63.2M
Total Current Liabilities	24.1M	22.8M	27.1M	57.6M	76.1M	79.9M
Property Plant And Equipment Net	1.0M	129.8K	4.0M	3.6M	3.7M	3.9M
Retained Earnings	(128.7M)	(53.7M)	(26.3M)	49.9M	121.3M	127.3M
Accounts Payable	4.1M	4.3M	2.8M	4.0M	14.8M	15.5M
Non Current Assets Total	1.0M	33.1M	27.7M	54.8M	252.6M	265.2M
Common Stock Total Equity	103.4K	103.8K	103K	105K	120.8K	66.6K
Property Plant And Equipment Gross	1.0M	129.8K	4.0M	3.6M	4.4M	4.6M
Accumulated Other Comprehensive Income	9.5K	31.3K	(148K)	24K	14K	14.7K
Common Stock	103.4K	103.8K	103K	105K	107K	69.1K
Property Plant Equipment	210.5K	129.8K	4.0M	847K	974.1K	1.0M
Other Current Assets	4.4M	8.3M	4.4M	5.2M	12.5M	13.2M
Non Current Liabilities Total	647.5K	4.3M	3.9M	17.6M	8.0M	8.4M
Net Tangible Assets	87.6M	169.6M	206.8M	268.0M	308.1M	323.5M
Retained Earnings Total Equity	(160.6M)	(128.7M)	(26.3M)	49.9M	57.3M	60.2M
Capital Surpluse	211.3M	216.2M	233.2M	250.4M	288.0M	169.1M
Inventory	2.0M	4.7M	7.9M	6.8M	15.6M	16.4M
Non Current Liabilities Other	154.8K	647.5K	3.9M	17.6M	485K	460.8K
Net Invested Capital	87.6M	169.6M	206.8M	300.4M	387.9M	201.8M
Net Working Capital	87.3M	136.5M	183.0M	263.2M	143.3M	147.7M
Capital Stock	103.4K	103.8K	103K	105K	107K	114.6K

Pair Trading with Catalyst Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Catalyst Stock

0.82	A	Agilent Technologies Financial Report 28th of May 2024	Pair Corr
0.81	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.76	ENVB	Enveric Biosciences Financial Report 20th of May 2024	Pair Corr

Moving against Catalyst Stock

0.43

DNA

Ginkgo Bioworks Holdings Financial Report 8th of May 2024

Pair Corr

The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.

The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock:

How To Invest In Catalyst

Details

Is Catalyst Stock a good investment?

Details

What is Catalyst Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Catalyst Stock analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Stocks Directory Find actively traded stocks across global markets
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.346

Earnings Share

0.63

Revenue Per Share

3.747

Quarterly Revenue Growth

0.82

Return On Assets

0.1283

The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Catalyst Other Current Liab vs Short Term Investments Analysis

Other Current Liab vs Short Term Investments

Other Current Liab vs Short Term Investments Correlation Analysis

Correlation Coefficient

Other Current Liab

Short Term Investments

Catalyst Pharmaceuticals fundamental ratios Correlations

Catalyst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Catalyst Pharmaceuticals fundamental ratios Accounts

Pair Trading with Catalyst Pharmaceuticals

Moving together with Catalyst Stock

Moving against Catalyst Stock

Complementary Tools for Catalyst Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Total Liab
Total Current Liabilities	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Cash

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Total Current Assets	- 0.97	Net Debt
Net Receivables	- 0.95	Non Currrent Assets Other
Non Currrent Assets Other	- 0.94	Accounts Payable
Non Currrent Assets Other	- 0.93	Non Current Assets Total